Adaptin Bio, Inc. (APTN) — Moat, Quality & Fair Value

Adaptin Bio, Inc. (APTN) is a recently listed company that began trading on March 17, 2026, operating in the Health Care sector. It carries an approximate market capitalization of $56M.

Full analysis is pending. MoatScope's moat rating, seven-pillar quality score, and owner-earnings fair value are built from audited financial statements in a company's periodic SEC filings (Form 10-K and 10-Q). As a newly public company, Adaptin Bio, Inc. has not yet filed its first periodic report, so there is not yet enough financial history to produce these estimates.

These ratings will populate automatically once APTN's first periodic filing is available — typically after its first full quarter as a public company. Check back then for the complete moat, quality, and fair-value analysis.

In the meantime, learn how the framework works: economic moats, the quality score, and owner-earnings fair value. Or browse analyzed stocks.

MoatScope

Stock Quality, Tracked.

Loading universe…

Screen every US stock through the lens of competitive advantage.

MoatScope rates 3,000+ US-listed stocks on a Quality × Valuation grid. Every analyzed company gets a moat rating (Wide, Narrow, or None), a 0–100 quality score, and a three-tier owner-earnings fair value estimate.

Wide / Narrow / None moat ratings on every analyzed stock, with full reasoning.
Seven-pillar quality score: profitability, capital efficiency, balance sheet, growth consistency, margin stability, cash conversion, capital allocation.
Owner-earnings fair value in three tiers (Conservative, Base, Optimistic).
Quality × Valuation scatter plot — find high-quality businesses trading below fair value at a glance.
SEC EDGAR-driven data — fundamentals come direct from XBRL filings.

About MoatScope · User guide · Blog · Pricing · FAQ